AR113221A1 - Agentes antifúngicos utilizados en combinación - Google Patents
Agentes antifúngicos utilizados en combinaciónInfo
- Publication number
- AR113221A1 AR113221A1 ARP180100881A ARP180100881A AR113221A1 AR 113221 A1 AR113221 A1 AR 113221A1 AR P180100881 A ARP180100881 A AR P180100881A AR P180100881 A ARP180100881 A AR P180100881A AR 113221 A1 AR113221 A1 AR 113221A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- antifungal agents
- filamentous fungi
- antifungal
- enfumafungin
- Prior art date
Links
- 229940121375 antifungal agent Drugs 0.000 title abstract 5
- 239000003429 antifungal agent Substances 0.000 title abstract 3
- 241000233866 Fungi Species 0.000 abstract 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 abstract 2
- 230000000843 anti-fungal effect Effects 0.000 abstract 2
- IAOFPTKYKOAKGZ-CRWQHXLTSA-N enfumafungin Chemical compound O([C@H]1[C@H](OC(C)=O)C[C@@]23C(O)OC[C@]1(C)[C@@H]2CC[C@@H]1[C@@]2(C)CC[C@]([C@H]([C@]2(C)CC=C13)C(O)=O)(C)[C@H](C)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IAOFPTKYKOAKGZ-CRWQHXLTSA-N 0.000 abstract 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 abstract 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
- 229920001503 Glucan Polymers 0.000 abstract 1
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
- 229960003942 amphotericin b Drugs 0.000 abstract 1
- 150000003851 azoles Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 for example Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- DDFOUSQFMYRUQK-RCDICMHDSA-N isavuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC=C(F)C=2)F)=NC=1C1=CC=C(C#N)C=C1 DDFOUSQFMYRUQK-RCDICMHDSA-N 0.000 abstract 1
- 229960000788 isavuconazole Drugs 0.000 abstract 1
- 229960004130 itraconazole Drugs 0.000 abstract 1
- 150000004291 polyenes Chemical class 0.000 abstract 1
- 229960001589 posaconazole Drugs 0.000 abstract 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 abstract 1
- 229960004740 voriconazole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Uso de compuestos antifúngicos triterpenoides derivados de enfumafungina, en combinación con otros agentes antifúngicos como por ejemplo, azoles, polienos, lipopéptidos y alilamidas para tratar enfermedades fúngicas. Más particularmente, combinaciones antifúngicas triterpenoides derivadas de enfumafungina (o sus sales farmacéuticamente aceptables) que son inhibidores de la síntesis de (1,3)-b-D-glucano, en combinación con otros agentes antifúngicos como por ejemplo, agentes activos en hongos filamentosos, que actúan contra hongos filamentosos, dichas combinaciones incluyen de manera enunciativa pero no limitativa, voriconazol, isavuconazol, posaconazol, itraconazol, y anfotericina B, para el tratamiento y/o prevención de infecciones producidas por hongos filamentosos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483647P | 2017-04-10 | 2017-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113221A1 true AR113221A1 (es) | 2020-02-19 |
Family
ID=62063223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100881A AR113221A1 (es) | 2017-04-10 | 2018-04-09 | Agentes antifúngicos utilizados en combinación |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11110102B2 (es) |
| EP (1) | EP3609539A1 (es) |
| JP (1) | JP7263313B2 (es) |
| KR (2) | KR20240110109A (es) |
| CN (1) | CN110769854B (es) |
| AR (1) | AR113221A1 (es) |
| AU (1) | AU2018253031B2 (es) |
| BR (1) | BR112019021138A2 (es) |
| CA (1) | CA3059225A1 (es) |
| EA (1) | EA201992413A1 (es) |
| MA (1) | MA49889A (es) |
| MX (1) | MX2019012116A (es) |
| TW (1) | TWI806861B (es) |
| WO (1) | WO2018191077A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49751B1 (fr) * | 2017-08-04 | 2022-12-30 | Scynexis Inc | Agents antifongiques à activité améliorée en ph acide |
| AU2020228036A1 (en) * | 2019-02-27 | 2021-09-23 | Scynexis, Inc. | Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia |
| MX2021013899A (es) * | 2019-05-16 | 2022-02-10 | Scynexis Inc | Agentes antifungicos para la descolinizacion de candida auris. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| ES2402659T3 (es) * | 2006-04-03 | 2013-05-07 | Merck Sharp & Dohme Corp. | Derivados de enfumafungina como agentes antifúngicos |
| US8188085B2 (en) | 2008-08-12 | 2012-05-29 | Merck Sharp & Dohme Corp. | Antifungal agents |
| EA018337B1 (ru) * | 2008-08-12 | 2013-07-30 | Мерк Шарп Энд Дом Корп. | Противогрибковые средства |
| JP6681894B2 (ja) * | 2014-11-21 | 2020-04-15 | エフツージー リミテッド | 抗真菌剤 |
| DK3247711T3 (da) | 2015-01-19 | 2022-05-09 | Scynexis Inc | Hidtil ukendte salte og polymorfer af scy-078 |
-
2018
- 2018-04-04 AU AU2018253031A patent/AU2018253031B2/en active Active
- 2018-04-04 EP EP18720489.6A patent/EP3609539A1/en active Pending
- 2018-04-04 MX MX2019012116A patent/MX2019012116A/es unknown
- 2018-04-04 CN CN201880033777.4A patent/CN110769854B/zh active Active
- 2018-04-04 MA MA049889A patent/MA49889A/fr unknown
- 2018-04-04 BR BR112019021138-1A patent/BR112019021138A2/pt unknown
- 2018-04-04 EA EA201992413A patent/EA201992413A1/ru unknown
- 2018-04-04 WO PCT/US2018/026088 patent/WO2018191077A1/en unknown
- 2018-04-04 KR KR1020247022473A patent/KR20240110109A/ko not_active Application Discontinuation
- 2018-04-04 JP JP2020504267A patent/JP7263313B2/ja active Active
- 2018-04-04 CA CA3059225A patent/CA3059225A1/en active Pending
- 2018-04-04 US US15/945,428 patent/US11110102B2/en active Active
- 2018-04-04 KR KR1020197032870A patent/KR102683355B1/ko active IP Right Grant
- 2018-04-09 AR ARP180100881A patent/AR113221A1/es unknown
- 2018-04-10 TW TW107112305A patent/TWI806861B/zh active
-
2021
- 2021-08-10 US US17/399,015 patent/US20220202833A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018253031B2 (en) | 2024-04-11 |
| JP2023030113A (ja) | 2023-03-07 |
| EA201992413A1 (ru) | 2020-03-16 |
| KR20190133251A (ko) | 2019-12-02 |
| EP3609539A1 (en) | 2020-02-19 |
| BR112019021138A2 (pt) | 2020-05-12 |
| CN110769854B (zh) | 2023-01-13 |
| US11110102B2 (en) | 2021-09-07 |
| JP7263313B2 (ja) | 2023-04-24 |
| KR102683355B1 (ko) | 2024-07-10 |
| TW201842915A (zh) | 2018-12-16 |
| US20180325919A1 (en) | 2018-11-15 |
| CN110769854A (zh) | 2020-02-07 |
| AU2018253031A1 (en) | 2019-10-31 |
| US20220202833A1 (en) | 2022-06-30 |
| TWI806861B (zh) | 2023-07-01 |
| KR20240110109A (ko) | 2024-07-12 |
| MX2019012116A (es) | 2019-11-21 |
| CA3059225A1 (en) | 2018-10-18 |
| JP2020513037A (ja) | 2020-04-30 |
| WO2018191077A1 (en) | 2018-10-18 |
| MA49889A (fr) | 2020-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| DOP2019000110A (es) | 1,2,4triazolonas 2,4,5trisustituidas | |
| ECSP13013035A (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida | |
| CO2017009023A2 (es) | Combinaciones de compuestos activos desde el punto de vista fungicida | |
| CL2020002757A1 (es) | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia transmenbrana de la fibrosis quística (divisional solicitud no. 2600-2016) | |
| AR112271A1 (es) | Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales | |
| CO2018012894A2 (es) | Derivados de pirazol como inhibidores de calicreína plasmática | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CL2020001394A1 (es) | Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina. | |
| ECSP12012243A (es) | Combinaciones de compuestos activos | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| ES2982308T3 (es) | Péptido novedoso y composición farmacéutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmacéutico activo | |
| CO2017005991A2 (es) | Una combinación fungicida que comprende una carboxamida de indanilo difluorometil-nicotínico y un inhibidor de la biosíntesis de ergosterol | |
| CO2017005990A2 (es) | Combinaciones de compuestos activos que comprenden (a) una carboxamida de indanilo difluorometil-nicotínico de fórmula (i) y otro compuesto activo como fungicida (b) | |
| CO2017006983A2 (es) | Una composición fungicida que comprende una n-ciclopropil- n-[bencilo sustituido]-3-(difluorometil)-5-fluoro-1- metil-1-h-pirazol-4-carboxamida o derivado de tiocarboxamida y dos compuestos fungicidas activos adicionales | |
| AR113221A1 (es) | Agentes antifúngicos utilizados en combinación | |
| CO2019011877A2 (es) | Nuevos derivados de pirazol bicíclicos | |
| CO2017005993A2 (es) | Combinaciones de compuestos activos | |
| UY37306A (es) | Combinaciones de compuestos activos | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| MY196425A (en) | Indazole Compounds For Use In Tendon And/Or Ligament Injuries | |
| NZ735783A (en) | Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof. | |
| UY37397A (es) | Combinaciones de compuestos activos | |
| AR103381A1 (es) | Composición farmacéutica para el tratamiento de micosis |